0
USD ▼
EUR USD GBP
+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Healthcare-associated Infectious Disease Diagnostics Market by Test Method, Pathogen Type, End User, Sample Type - Global Forecast to 2030- Product Image
Healthcare-associated Infectious Disease Diagnostics Market by Test Method, Pathogen Type, End User, Sample Type - Global Forecast to 2030- Product Image
Sale

Healthcare-associated Infectious Disease Diagnostics Market by Test Method, Pathogen Type, End User, Sample Type - Global Forecast to 2030

  • PDF Icon

    Report

  • 199 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5181418
UP TO EUR$697USDGBP OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Healthcare-associated Infectious Disease Diagnostics Market grew from USD 4.37 billion in 2024 to USD 4.76 billion in 2025. It is expected to continue growing at a CAGR of 8.39%, reaching USD 7.10 billion by 2030.

Harnessing Diagnostic Innovations to Combat Healthcare-Associated Infections

Healthcare-associated infectious diseases remain a pressing concern for providers, payers, and patients alike. As hospitals and clinics worldwide strive to minimize the incidence of infections acquired within care settings, diagnostic tools have taken center stage. Rapid, accurate detection of pathogens not only informs targeted therapy but also underpins infection control protocols that safeguard vulnerable populations. Against a backdrop of rising antimicrobial resistance and shifting regulatory landscapes, the diagnostics market is experiencing an unprecedented pace of innovation.

This executive summary distills the most salient trends, opportunities, and challenges shaping the future of healthcare-associated infectious disease diagnostics. Drawing on the latest industry data, regulatory analyses, and expert interviews, it offers an integrated perspective on transformative technological advances, the ripple effects of new trade policy measures, and the competitive dynamics among leading players. By synthesizing segmentation insights and regional nuances, this report equips decision-makers with the clarity needed to align strategic initiatives with market realities. Each section unfolds a critical dimension of the market-from methodological breakthroughs to actionable recommendations-ensuring that stakeholders can chart a course toward resilient growth and improved patient outcomes.

Unleashing a New Era of Rapid and Data-Driven Diagnostics

Recent years have witnessed a seismic shift in the diagnostic landscape for healthcare-associated infections. Molecular methods once deemed experimental have graduated to clinical routine, enabling turnaround times measured in hours rather than days. Next-generation sequencing platforms are revealing complex microbial ecologies, empowering clinicians to detect co-infections and emerging resistance markers that would otherwise evade conventional tests. Simultaneously, advances in immunoassay sensitivity and specificity are transforming point-of-care testing, extending accurate diagnostics beyond centralized laboratories into clinics and even patient homes.

Converging forces are accelerating this transformation. Digital health integration is facilitating real-time data sharing, bolstering antimicrobial stewardship efforts and outbreak surveillance. Automation and robotics are streamlining laboratory workflows, driving down per-test costs while enhancing reproducibility. Meanwhile, regulatory agencies have introduced expedited pathways for breakthrough diagnostics, incentivizing developers to address unmet clinical needs. Together, these shifts are forging a more agile, decentralized, and data-driven ecosystem for infection detection and management.

Navigating the Ripple Effects of 2025 U.S. Tariff Adjustments

The introduction of revised U.S. tariffs in early 2025 has unleashed a profound impact on the diagnostic supply chain. With increased duties on imported reagents, consumables, and instrumentation components, laboratories and test developers have faced escalating input costs. These added expenses have prompted critical reassessments of sourcing strategies, with many stakeholders exploring domestic manufacturing partnerships to mitigate exposure to tariff volatility.

Beyond cost pressures, the tariff changes have also reshaped competitive dynamics. Established multinational suppliers have leveraged local production capabilities to sustain margin targets, while smaller innovators have scrambled to find tariff-exempt exemptions or alternative shipping routes. The tariff landscape has prompted procurement teams to adopt a more holistic risk evaluation, factoring in potential disruptions alongside price. In this evolving context, agility and supply chain resilience have become as crucial as assay performance in securing long-term market presence.

Decoding Market Niches Across Methods, Pathogens, Users, and Samples

A nuanced understanding of market segmentation reveals the diverse technological and clinical niches within infectious disease diagnostics. Test method segmentation highlights immunoassays, microbiology, and molecular diagnostics as the primary pillars. Within immunoassays, chemiluminescent techniques have gained traction for high-throughput settings, while lateral flow assays are carving out expanded roles at the bedside. Traditional microbiology methods, from aerobic and anaerobic culture to advanced sensitivity testing, maintain their status as diagnostic mainstays, even as rapid molecular approaches like PCR and isothermal amplification continue to capture attention. Sequencing technologies further enrich this landscape by delivering comprehensive pathogen profiles.

Pathogen-based segmentation underscores the spectrum of clinical challenges. Bacterial pathogens such as Clostridium difficile, Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus remain top priorities for surveillance and rapid identification. Fungal threats, including Aspergillus and Candida species, demand specialized detection platforms, particularly in immunocompromised populations. Parasitic agents like malaria parasites and Toxoplasma gondii persist in certain hospital settings, while viral diagnostics spanning coronavirus, influenza, norovirus, and respiratory syncytial virus have been thrust into the limelight by recent global health events.

End user segmentation illuminates the distinct needs of diagnostic laboratories, hospitals, and point-of-care settings. Reference laboratories prioritize high-throughput, multiplexed platforms to serve wide catchment areas. Hospital pathology and microbiology laboratories emphasize rapid turnaround and integration with electronic medical records. Point-of-care venues, including clinics, emergency departments, and long-term care facilities, seek robust, easy-to-use systems that deliver actionable results within the course of a patient encounter.

Sample type segmentation further refines the diagnostic approach. Blood specimens, encompassing serum and whole blood, present opportunities for systemic infection screening. Cerebrospinal fluid demands ultra-sensitive assays for central nervous system pathogens. Respiratory samples like bronchoalveolar lavage and nasopharyngeal swabs have driven innovation in rapid viral and bacterial panels, while urine and wound swab analyses continue to rely on culture and molecular overlays for definitive identification.

Unearthing Regional Dynamics Shaping Market Trajectories

Regional dynamics exert a profound influence on market growth trajectories and adoption patterns. The Americas region remains a leader in advanced diagnostic deployment, propelled by strong reimbursement frameworks and ongoing investments in healthcare infrastructure. Regulatory harmonization efforts across key markets are fostering streamlined approvals, further accelerating market entry for novel platforms.

In Europe, Middle East & Africa, regulatory landscapes exhibit greater heterogeneity, with individual approval pathways and reimbursement models shaping commercialization strategies. Here, partnerships with local distributors and strategic alliances with public health agencies are essential to navigate diverse requirements and drive uptake. Infrastructure gaps in certain jurisdictions underscore the need for portable, low-maintenance solutions that can function in resource-constrained environments.

Asia-Pacific offers a tapestry of opportunities driven by large patient volumes, rising awareness of hospital-acquired infections, and government-led diagnostics modernization initiatives. Rapid urbanization and expanding private healthcare networks are fueling demand for point-of-care testing and high-throughput laboratory systems. However, varied reimbursement mechanisms and cost sensitivities necessitate tailored pricing and distribution models to capture market share across this dynamic region.

Mapping Competitive Forces and Innovation Frontiers

The competitive landscape is marked by established diagnostics giants alongside agile innovators driving disruptive technologies. Leading corporations have fortified their positions through mergers, strategic acquisitions, and expansion of comprehensive assay portfolios spanning immunoassays, molecular panels, and integrated laboratory systems. These players leverage global distribution networks and robust service offerings to maintain customer loyalty and drive recurring revenue streams.

Emerging companies, meanwhile, differentiate themselves through specialized platforms that address niche clinical needs or operational gaps. For instance, firms focused on rapid molecular identification of antimicrobial resistance markers are attracting interest from hospital networks committed to stewardship programs. Others are pioneering digital diagnostics that combine artificial intelligence with assay data to optimize workflow and reduce reporting errors. The interplay between broad-spectrum incumbents and nimble startups underscores an ecosystem where collaboration and co-development alliances are increasingly prevalent.

Strategic Priorities to Advance Diagnostics Leadership

Industry leaders should prioritize investments in adaptable, modular diagnostic platforms that can rapidly incorporate new assays and resistance markers. By aligning R&D roadmaps with emerging clinical guidelines and regulatory incentives, companies can accelerate time to market and enhance clinical relevance. Supply chain diversification, including onshore manufacturing partnerships and multi-sourcing agreements, will mitigate the impact of geopolitical and tariff-related disruptions.

Stakeholders should also deepen collaborations with healthcare providers and public health agencies to co-create integrated solutions that address workflow bottlenecks and data interoperability challenges. Engaging in pilot programs and real-world evidence studies will generate compelling value propositions and strengthen reimbursement dossiers. Additionally, embedding digital health tools and AI-driven analytics into diagnostic platforms can unlock new service-based revenue streams and support precision infection management.

Comprehensive, Rigorous Approach to Data and Insights

This research synthesizes qualitative and quantitative inputs from a broad spectrum of sources. Primary data were gathered through structured interviews with senior executives, laboratory directors, and clinical experts across major healthcare markets. Secondary research encompassed peer-reviewed literature, regulatory filings, patent databases, and industry publications.

Market segmentation frameworks were developed by systematically categorizing diagnostic methodologies, pathogen targets, end user channels, and specimen types based on consensus nomenclature and emerging clinical use cases. Regional analyses integrated trade policy reviews, reimbursement landscape assessments, and infrastructure evaluations. Competitive profiling leveraged financial reports, M&A announcements, and public disclosures to map corporate strategies and innovation pipelines.

Rigorous validation protocols, including triangulation of multiple data streams and corroboration with independent expert panels, ensured the reliability and relevance of the findings. Continuous data quality checks and periodic updates sustained the accuracy of the insights presented herein.

Charting a Resilient Path Forward in Diagnostics

As healthcare systems contend with persistent and emerging infectious threats, the demand for rapid, reliable diagnostics will only intensify. The interplay of technological breakthroughs, regulatory reforms, and macroeconomic forces will shape a market defined by agility, precision, and collaboration. By understanding the nuanced contours of market segmentation and regional dynamics, and by anticipating policy-driven shifts, stakeholders can position themselves to capture growth and drive better patient outcomes.

The strategic imperatives outlined-from modular platform design to supply chain resilience and integrated digital solutions-offer a roadmap for organizations seeking to lead in this critical domain. In an era where timely diagnosis can mean the difference between containment and outbreak, the insights presented in this summary form the foundation for informed decision-making and sustained competitive advantage.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Test Method
    • Immunoassays
      • Chemiluminescent Immunoassay
      • ELISA
      • Lateral Flow Assays
    • Microbiology
      • Culture
        • Aerobic Culture
        • Anaerobic Culture
      • Microscopy
      • Sensitivity Testing
    • Molecular Diagnostics
      • Isothermal Amplification
      • PCR
      • Sequencing
  • Pathogen Type
    • Bacterial
      • Clostridium Difficile
      • Escherichia Coli
      • Pseudomonas Aeruginosa
      • Staphylococcus Aureus
    • Fungal
      • Aspergillus Species
      • Candida Species
      • Cryptococcus Neoformans
    • Parasitic
      • Malaria Parasites
      • Toxoplasma Gondii
    • Viral
      • Coronavirus
      • Influenza Virus
      • Norovirus
      • Respiratory Syncytial Virus
  • End User
    • Diagnostic Laboratories
      • Independent Laboratories
      • Reference Laboratories
    • Hospitals
      • Clinical Pathology Laboratories
      • Microbiology Laboratories
    • Point Of Care
      • Clinics
      • Emergency Departments
      • Long Term Care Facilities
  • Sample Type
    • Blood
      • Serum
      • Whole Blood
    • Cerebrospinal Fluid
    • Respiratory
      • Bronchoalveolar Lavage
      • Nasopharyngeal Swabs
      • Sputum
    • Urine
      • Catheterized Urine
      • Midstream Urine
    • Wound Swabs
      • Deep Tissue Samples
      • Surface Swabs
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Roche Diagnostics International AG
  • Abbott Laboratories
  • Danaher Corporation
  • Thermo Fisher Scientific Inc.
  • Siemens Healthineers AG
  • Becton, Dickinson and Company
  • bioMérieux SA
  • QIAGEN N.V.
  • Bio-Rad Laboratories, Inc.
  • DiaSorin S.p.A.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Healthcare-associated Infectious Disease Diagnostics Market, by Test Method
8.1. Introduction
8.2. Immunoassays
8.2.1. Chemiluminescent Immunoassay
8.2.2. ELISA
8.2.3. Lateral Flow Assays
8.3. Microbiology
8.3.1. Culture
8.3.1.1. Aerobic Culture
8.3.1.2. Anaerobic Culture
8.3.2. Microscopy
8.3.3. Sensitivity Testing
8.4. Molecular Diagnostics
8.4.1. Isothermal Amplification
8.4.2. PCR
8.4.3. Sequencing
9. Healthcare-associated Infectious Disease Diagnostics Market, by Pathogen Type
9.1. Introduction
9.2. Bacterial
9.2.1. Clostridium Difficile
9.2.2. Escherichia Coli
9.2.3. Pseudomonas Aeruginosa
9.2.4. Staphylococcus Aureus
9.3. Fungal
9.3.1. Aspergillus Species
9.3.2. Candida Species
9.3.3. Cryptococcus Neoformans
9.4. Parasitic
9.4.1. Malaria Parasites
9.4.2. Toxoplasma Gondii
9.5. Viral
9.5.1. Coronavirus
9.5.2. Influenza Virus
9.5.3. Norovirus
9.5.4. Respiratory Syncytial Virus
10. Healthcare-associated Infectious Disease Diagnostics Market, by End User
10.1. Introduction
10.2. Diagnostic Laboratories
10.2.1. Independent Laboratories
10.2.2. Reference Laboratories
10.3. Hospitals
10.3.1. Clinical Pathology Laboratories
10.3.2. Microbiology Laboratories
10.4. Point of Care
10.4.1. Clinics
10.4.2. Emergency Departments
10.4.3. Long Term Care Facilities
11. Healthcare-associated Infectious Disease Diagnostics Market, by Sample Type
11.1. Introduction
11.2. Blood
11.2.1. Serum
11.2.2. Whole Blood
11.3. Cerebrospinal Fluid
11.4. Respiratory
11.4.1. Bronchoalveolar Lavage
11.4.2. Nasopharyngeal Swabs
11.4.3. Sputum
11.5. Urine
11.5.1. Catheterized Urine
11.5.2. Midstream Urine
11.6. Wound Swabs
11.6.1. Deep Tissue Samples
11.6.2. Surface Swabs
12. Americas Healthcare-associated Infectious Disease Diagnostics Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Healthcare-associated Infectious Disease Diagnostics Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Healthcare-associated Infectious Disease Diagnostics Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Roche Diagnostics International AG
15.3.2. Abbott Laboratories
15.3.3. Danaher Corporation
15.3.4. Thermo Fisher Scientific Inc.
15.3.5. Siemens Healthineers AG
15.3.6. Becton, Dickinson and Company
15.3.7. bioMérieux SA
15.3.8. QIAGEN N.V.
15.3.9. Bio-Rad Laboratories, Inc.
15.3.10. DiaSorin S.p.A.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET MULTI-CURRENCY
FIGURE 2. HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET MULTI-LANGUAGE
FIGURE 3. HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2024 VS 2030 (%)
FIGURE 8. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ELISA, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY AEROBIC CULTURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ANAEROBIC CULTURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROSCOPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SENSITIVITY TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CLOSTRIDIUM DIFFICILE, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ESCHERICHIA COLI, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PSEUDOMONAS AERUGINOSA, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY STAPHYLOCOCCUS AUREUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ASPERGILLUS SPECIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CANDIDA SPECIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CRYPTOCOCCUS NEOFORMANS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MALARIA PARASITES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TOXOPLASMA GONDII, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CORONAVIRUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INFLUENZA VIRUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY NOROVIRUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CLINICAL PATHOLOGY LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY EMERGENCY DEPARTMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY LONG TERM CARE FACILITIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SERUM, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CEREBROSPINAL FLUID, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BRONCHOALVEOLAR LAVAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY NASOPHARYNGEAL SWABS, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SPUTUM, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CATHETERIZED URINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MIDSTREAM URINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 76. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, BY REGION, 2018-2030 (USD MILLION)
TABLE 77. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DEEP TISSUE SAMPLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 78. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SURFACE SWABS, BY REGION, 2018-2030 (USD MILLION)
TABLE 79. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 92. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 93. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, 2018-2030 (USD MILLION)
TABLE 94. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 95. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 96. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, 2018-2030 (USD MILLION)
TABLE 97. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 98. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, 2018-2030 (USD MILLION)
TABLE 99. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 100. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2018-2030 (USD MILLION)
TABLE 101. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 102. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, 2018-2030 (USD MILLION)
TABLE 103. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, 2018-2030 (USD MILLION)
TABLE 104. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 105. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 106. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 107. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, 2018-2030 (USD MILLION)
TABLE 108. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, 2018-2030 (USD MILLION)
TABLE 109. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2030 (USD MILLION)
TABLE 110. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 111. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 112. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 113. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, 2018-2030 (USD MILLION)
TABLE 114. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 115. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 116. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, 2018-2030 (USD MILLION)
TABLE 117. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 118. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, 2018-2030 (USD MILLION)
TABLE 119. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 120. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2018-2030 (USD MILLION)
TABLE 121. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 122. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, 2018-2030 (USD MILLION)
TABLE 123. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, 2018-2030 (USD MILLION)
TABLE 124. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 125. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 126. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 127. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, 2018-2030 (USD MILLION)
TABLE 128. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, 2018-2030 (USD MILLION)
TABLE 129. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2030 (USD MILLION)
TABLE 130. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 131. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 132. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 133. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, 2018-2030 (USD MILLION)
TABLE 134. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 135. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 136. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, 2018-2030 (USD MILLION)
TABLE 137. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 138. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, 2018-2030 (USD MILLION)
TABLE 139. MEXICO HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2018-2030 (USD MILLION)
TABLE 140. MEXICO HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 141. MEXICO HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, 2018-2030 (USD MILLION)
TABLE 142. MEXICO HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, 2018-2030 (USD MILLION)
TABLE 143. MEXICO HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 144. MEXICO HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 145. MEXICO HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 146. MEXICO HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, 2018-2030 (USD MILLION)
TABLE 147. MEXICO HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, 2018-2030 (USD MILLION)
TABLE 148. MEXICO HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2030 (USD MILLION)
TABLE 149. MEXICO HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 150. MEXICO HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 151. MEXICO HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 152. MEXICO HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, 2018-2030 (USD MILLION)
TABLE 153. MEXICO HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 154. MEXICO HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 155. MEXICO HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, 2018-2030 (USD MILLION)
TABLE 156. MEXICO HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 157. MEXICO HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, 2018-2030 (USD MILLION)
TABLE 158. BRAZIL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2018-2030 (USD MILLION)
TABLE 159. BRAZIL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 160. BRAZIL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, 2018-2030 (USD MILLION)
TABLE 161. BRAZIL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, 2018-2030 (USD MILLION)
TABLE 162. BRAZIL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 163. BRAZIL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 164. BRAZIL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 165. BRAZIL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, 2018-2030 (USD MILLION)
TABLE 166. BRAZIL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, 2018-2030 (USD MILLION)
TABLE 167. BRAZIL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2030 (USD MILLION)
TABLE 168. BRAZIL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 169. BRAZIL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 170. BRAZIL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 171. BRAZIL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, 2018-2030 (USD MILLION)
TABLE 172. BRAZIL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 173. BRAZIL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 174. BRAZIL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, 2018-2030 (USD MILLION)
TABLE 175. BRAZIL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 176. BRAZIL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, 2018-2030 (USD MILLION)
TABLE 177. ARGENTINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2018-2030 (USD MILLION)
TABLE 178. ARGENTINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 179. ARGENTINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, 2018-2030 (USD MILLION)
TABLE 180. ARGENTINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, 2018-2030 (USD MILLION)
TABLE 181. ARGENTINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 182. ARGENTINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 183. ARGENTINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 184. ARGENTINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, 2018-2030 (USD MILLION)
TABLE 185. ARGENTINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, 2018-2030 (USD MILLION)
TABLE 186. ARGENTINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2030 (USD MILLION)
TABLE 187. ARGENTINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 188. ARGENTINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 189. ARGENTINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 190. ARGENTINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, 2018-2030 (USD MILLION)
TABLE 191. ARGENTINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 192. ARGENTINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 193. ARGENTINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, 2018-2030 (USD MILLION)
TABLE 194. ARGENTINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 195. ARGENTINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, 2018-2030 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2018-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, 2018-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, 2018-2030 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, 2018-2030 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, 2018-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2030 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, 2018-2030 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, 2018-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, 2018-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 216. UNITED KINGDOM HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2018-2030 (USD MILLION)
TABLE 217. UNITED KINGDOM HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 218. UNITED KINGDOM HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, 2018-2030 (USD MILLION)
TABLE 219. UNITED KINGDOM HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, 2018-2030 (USD MILLION)
TABLE 220. UNITED KINGDOM HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 221. UNITED KINGDOM HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 222. UNITED KINGDOM HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 223. UNITED KINGDOM HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, 2018-2030 (USD MILLION)
TABLE 224. UNITED KINGDOM HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, 2018-2030 (USD MILLION)
TABLE 225. UNITED KINGDOM HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2030 (USD MILLION)
TABLE 226. UNITED KINGDOM HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 227. UNITED KINGDOM HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 228. UNITED KINGDOM HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, 2018-2030 (USD MILLION)
TABLE 230. UNITED KINGDOM HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 232. UNITED KINGDOM HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, 2018-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 234. UNITED KINGDOM HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, 2018-2030 (USD MILLION)
TABLE 235. GERMANY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2018-2030 (USD MILLION)
TABLE 236. GERMANY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 237. GERMANY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, 2018-2030 (USD MILLION)
TABLE 238. GERMANY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, 2018-2030 (USD MILLION)
TABLE 239. GERMANY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 240. GERMANY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
TABLE 241. GERMANY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2030 (USD MILLION)
TABLE 242. GERMANY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, 2018-2030 (USD MILLION)
TABLE 243. GERMANY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, 2018-2030 (USD MILLION)
TABLE 244. GERMANY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2030 (USD MILLION)
TABLE 245. GERMANY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 246. GERMANY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 247. GERMANY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 248. GERMANY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, 2018-2030 (USD MILLION)
TABLE 249. GERMANY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 250. GERMANY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 251. GERMANY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, 2018-2030 (USD MILLION)
TABLE 252. GERMANY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 253. GERMANY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, 2018-2030 (USD MILLION)
TABLE 254. FRANCE HEALTH

Companies Mentioned

The companies profiled in this Healthcare-associated Infectious Disease Diagnostics market report include:
  • Roche Diagnostics International AG
  • Abbott Laboratories
  • Danaher Corporation
  • Thermo Fisher Scientific Inc.
  • Siemens Healthineers AG
  • Becton, Dickinson and Company
  • bioMérieux SA
  • QIAGEN N.V.
  • Bio-Rad Laboratories, Inc.
  • DiaSorin S.p.A.

Methodology

Methodology DOWNLOAD NOW

Table Information

Report AttributeDetails
No. of Pages199
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 4.76 Billion
Forecasted Market Value ( USD ) by 2030 $ 7.1 Billion
Compound Annual Growth Rate8.3%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Hospital Acquired Disease Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Hospital Acquired Disease Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 180 Pages
  • Global
From
EUR$4,500USDGBP
Hospital Acquired Infections Diagnostics Market Size, Share & Trends Analysis Report by Test (Molecular, Conventional), Infection (UTI, Pneumonia), Product, Type, and Region with Growth Forecasts, 2025-2030 - Product Image

Hospital Acquired Infections Diagnostics Market Size, Share & Trends Analysis Report by Test (Molecular, Conventional), Infection (UTI, Pneumonia), Product, Type, and Region with Growth Forecasts, 2025-2030

  • Report
  • 70 Pages
  • Global
From
EUR$5,950USDGBP
Hospital Acquired Infections Testing Kits Market Report 2025 - Product Image

Hospital Acquired Infections Testing Kits Market Report 2025

  • Report
  • 250 Pages
  • Global
From
EUR$4,490USDGBP
Hospital Acquired Infections Testing Kits Market Innovations and Strategic Insights Report - Market Data, Trends, Market Potential, Competitive Analysis and Growth Forecasts (2024 to 2032) - Product Image

Hospital Acquired Infections Testing Kits Market Innovations and Strategic Insights Report - Market Data, Trends, Market Potential, Competitive Analysis and Growth Forecasts (2024 to 2032)

  • Report
  • 153 Pages
  • Global
From
EUR$4,250USDGBP
Hospital Acquired Disease Testing Market Report by Indication (UTI (Urinary Tract Infection), SSI (Surgical Site Infection), Pneumonia, Bloodstream Infections, MRSA (Methicillin-Resistant Staphylococcus Aureus), and Others), and Region 2025-2033 - Product Image

Hospital Acquired Disease Testing Market Report by Indication (UTI (Urinary Tract Infection), SSI (Surgical Site Infection), Pneumonia, Bloodstream Infections, MRSA (Methicillin-Resistant Staphylococcus Aureus), and Others), and Region 2025-2033

  • Report
  • 146 Pages
  • Global
From
EUR$2,999USDGBP

About the Hospital Acquired Infection Diagnostics Market

The Hospital Acquired Infection Diagnostics market is a subset of the Infectious Disease Testing market. It focuses on the diagnosis of infections acquired in a hospital setting, such as Methicillin-resistant Staphylococcus aureus (MRSA) and Clostridium difficile (C. diff). Diagnostics for these infections are typically conducted using molecular testing, such as polymerase chain reaction (PCR) and next-generation sequencing (NGS). These tests are used to detect the presence of the pathogen, as well as to identify the strain and its resistance to antibiotics. The Hospital Acquired Infection Diagnostics market is driven by the increasing prevalence of hospital-acquired infections, as well as the need for rapid and accurate diagnosis. This is especially important in the case of antibiotic-resistant infections, as timely diagnosis and treatment can help reduce the spread of the infection. Some companies in the Hospital Acquired Infection Diagnostics market include Cepheid, Hologic, Becton Dickinson, Roche, and Abbott. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.
This website uses cookies to ensure you get the best experience. Learn more